(Q44837135)

English

Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology

scientific article published in April 2004

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

author name string

Sabine Wagner

1

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Bernhard Erdlenbruch

2

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Alfred Längler

3

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Astrid Gnekow

4

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Joachim Kühl

5

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Michael Albani

6

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Sigrid Völpel

7

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Peter Bucsky

8

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Angela Emser

9

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Ove Peters

10

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Johannes E A Wolff

11

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

language of work or name

0 references

publication date

1 April 2004

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

100

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1750-1757

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Urinary and fecal excretion of topotecan in patients with malignant solid tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20168

21 January 2018

Efficacy and toxicity profile of oral topotecan in a panel of human tumour xenografts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20168

21 January 2018

Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20168

21 January 2018

A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20168

21 January 2018

Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20168

21 January 2018

Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20168

21 January 2018

Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20168

21 January 2018

Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20168

21 January 2018

Oral trofosfamide and etoposide in pediatric patients with glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20168

21 January 2018

A North Central Cancer Treatment Group phase II trial of topotecan in relapsed gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20168

21 January 2018

Clinical pharmacokinetics of topotecan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20168

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20168

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II evaluation of topotecan for pediatric central nervous system tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20168

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20168

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative activity of oral and parenteral topotecan in murine tumor models: efficacy of oral topotecan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20168

7 January 2021

based on heuristic

inferred from DOI database lookup

Improvement of therapeutic index of low-dose topotecan delivered per os

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20168

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20168

7 January 2021

based on heuristic

inferred from DOI database lookup

Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed-phase liquid chromatography with fluorescence detection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20168

7 January 2021

based on heuristic

inferred from DOI database lookup

Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20168

7 January 2021

based on heuristic

inferred from DOI database lookup

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20168

7 January 2021

based on heuristic

inferred from DOI database lookup

Schedule-dependent efficacy of camptothecins in models of human cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20168

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.20168

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44837135&oldid=2048895226"